First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with ...

Researchers found that smaller cancer cells with doubled DNA often behaved more aggressively than larger ones.

Early ASCO data for OP-3136 pointed to encouraging anti-cancer activity with a clean safety profile, adding momentum to ...

OptiTROP-Lung05 randomized 413 untreated, PD-L1 ≥1% advanced NSCLC patients without EGFR/ALK alterations to sac-TMT+pembrolizumab versus pembrolizumab; primary endpoint was PFS. Median PFS was not ...

BOSTON, MA / ACCESS Newswire / May 20, 2026 / When people think of lung cancer, they rarely think of their zip code as a risk ...

Researchers have demonstrated a promising new approach to stopping pancreatic cancer before it starts, using experimental drugs to eliminate microscopic precancerous lesions in the pancreas.

BOSTON, MA / ACCESS Newswire / May 20, 2026 / When people think of lung cancer, they rarely think of their zip code as a risk factor. But for the tens of thousands of Americans whose cancer stems from ...

Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 ---- Systemic lung ...

In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard ...

The soft tissue sarcoma with lung metastases market across the 7MM is projected to demonstrate steady growth during the 2026-2036 forecast period, driven primarily by the anticipated launch ...